Rituximab plus chlorambucil extend event-free survival in MALT lymphoma The Oncology Report Patients who have mucosa-associated lymphoid tissue lymphoma and are treated with chlorambucil plus rituximab have better event-free survival and progression-free survival than do comparable patients treated with either drug alone, according to ... |
